Ryan Wang

Vice President, Lilly China External Innovation at Eli Lilly and Company

Presenter

Ryan Wang is Vice President, Head of Lilly China External Innovation, with the mission to form innovation partnerships with China leading biotech companies and academic institutions. Ryan is dedicated to cultivating original innovation and enabling biotech start-ups. Since joining Lilly in 2019, Ryan has led Lilly China Innovation&Partnerships (LCIP) team forming a number of innovation partnerships with China biotechs, including the deals with Junshi (CoVID-19 antibody, 2020), Regor (2021), and the recently announced partnerships with Sanegene, Xtalpi, In Silico Med, and AlphaMa. In early 2022, under Ryan’s leadership, LCIP opened its Catalyst office at Zhangjiang, Shanghai, and launched China Research Fund to support translational research from idea to hit ID, so far China Research Fund has sponsored more than 15 research collaboration projects. Since May 2025, Ryan has expanded his role to oversee the overall Lilly External Innovation business in China. Before joining Lilly, Ryan spent more than 12 years on Pharma R&D with GSK and has proven track record in leading cross-discipline project team to achieve successful IND submissions in US in areas of Immunology, Neuroscience and Infectious Disease. Ryan was trained as a biologist at Shanghai Institutes for Biological Sciences, China Academy of Sciences and obtained his Ph.D. in 2008.